Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
JP Leonard, M Coleman, JC Ketas… - Journal of clinical …, 2003 - ascopubs.org
Purpose: This single-center, dose-escalation study examines the safety, efficacy, and
pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients
with recurrent indolent non-Hodgkin's lymphoma (NHL). Patients and Methods: Patients had
indolent NHL and recurrent disease after at least one chemotherapy regimen. Epratuzumab
was administered intravenously at 120 to 1,000 mg/m2 over 30 to 60 minutes weekly for four
treatments. Results: Fifty-five patients received epratuzumab and were assessable for safety; …
pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients
with recurrent indolent non-Hodgkin's lymphoma (NHL). Patients and Methods: Patients had
indolent NHL and recurrent disease after at least one chemotherapy regimen. Epratuzumab
was administered intravenously at 120 to 1,000 mg/m2 over 30 to 60 minutes weekly for four
treatments. Results: Fifty-five patients received epratuzumab and were assessable for safety; …
[引用][C] Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL)
L JP - Blood, 2002 - cir.nii.ac.jp
Phase I/II trial of Epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's
lymphoma (NHL) | CiNii Research … Phase I/II trial of Epratuzumab (humanized anti-CD22
antibody) in non-Hodgkin's lymphoma (NHL) …
lymphoma (NHL) | CiNii Research … Phase I/II trial of Epratuzumab (humanized anti-CD22
antibody) in non-Hodgkin's lymphoma (NHL) …